EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ginsenoside Rg3 Ameliorates Psoriasis‐Like Dermatitis through Inhibition of NF‐κB/NLRP3 Inflammasome Signaling and Regulating Th17/Treg Balance

Liyun Gao, Qingge Xie, Zhaoli Zhou, Wanlu Zhang, Huiya Sun, Zhen Yue, Congjun Jiang iD

Immunity, Inflammation and Disease · 2026-02 · 14 (2)

DOI: 10.1002/iid3.70362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 16.02.2026. Verfasst von Liyun Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical University, Bengbu, Anhui, China. Hauptthemen laut MEDLINE: Ginsenosides, Psoriasis, NLR Family, Pyrin Domain-Containing 3 Protein, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Longhu Talent Project of Bengbu Medical University, Natural Science Innovation Program for Master's Students at Bengbu Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Psoriasis, characterized as a persistent cutaneous inflammatory condition driven by aberrant immunity, exhibits pathogenesis and disease course heavily influenced by sustained inflammatory activity. Ginsenoside Rg3 (Grg3), a traditional Chinese medicinal compound, has shown notable therapeutic effects on various inflammatory diseases. However, its therapeutic efficacy and mechanisms of action in the treatment of psoriasis remain unclear.

Method

In this study, we utilized 6 to 8‐week‐old female BALB/c mice and applied 5% imiquimod (IMQ) cream to their dorsal skin to establish a psoriasis‐like dermatitis model. Twenty‐five mice were randomly divided into five groups: control, model, and the Grg3‐L/M/H groups, receiving dosages of 5, 10, and 20 mg/kg/day, respectively, with three mice in each group. Grg3 was administered continuously for 7 days to evaluate its effects on the skin of the psoriasis mice. The following methodologies were employed: the Psoriasis Area and Severity Index) for clinical severity scoring, hematoxylin‐eosin staining for histomorphological analysis, alongside immunohistochemistry, immunofluorescence, and flow cytometry for detailed protein and cellular profiling to assess the expression levels of the keratinocyte proliferation marker Ki‐67, inflammatory cytokines, NLRP3 inflammasome‐related factors, and NF‐κB pathway‐related proteins in vivo.

Result

Significant reductions in PASI scores were observed in IMQ‐treated BALB/c murine models of psoriasis following Grg3 treatment. It decreases epidermal thickness, inhibits the proliferation and differentiation of epidermal cells, and reduces the expression of the inflammatory cytokine interleukin‐17 (IL‐17) in splenic lymphocytes. Additionally, an increase in Foxp3 + CD4+ regulatory T cell (Treg) proportion and a decrease in the expression levels of NLRP3, apoptosis‐associated speck‐like protein (ASC), caspase‐1, and IL‐1β were observed following Grg3 administration. Furthermore, A concomitant downregulation of p‐p65 expression and its downstream effectors, such as the pro‐inflammatory cytokines interleukin‐6 (IL‐6) and tumor necrosis factor‐alpha (TNF‐α), was also observed.

Conclusion

Our findings indicate that Grg3 confers protective effects in a murine model of imiquimod‐induced psoriasis‐like dermatitis. The potential therapeutic properties of Grg3 potentially involve modulation of NLRP3 inflammasome activation, suppression of NF‐κB signaling, and restoration of Th17/Treg cell homeostasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GinsenosidesPsoriasisNLR Family, Pyrin Domain-Containing 3 ProteinT-Lymphocytes, RegulatoryNF-kappa BTh17 CellsInflammasomesDermatitisAnimalsFemaleSignal TransductionMiceMice, Inbred BALB CDisease Models, AnimalImiquimodHumansSkin

Stichwörter der Autor:innen

Ginsenoside Rg3NF‐κBNLRP3Th17/Tregpsoriasis

Substanzen

GinsenosidesNLR Family, Pyrin Domain-Containing 3 ProteinNF-kappa Bginsenoside Rg3InflammasomesNlrp3 protein, mouseImiquimod

Autor:innen und Institutionen

  • Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical University, Bengbu, Anhui, China.
  • Department of Dermatology, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
  • School of Laboratory, Bengbu Medical University, Bengbu, Anhui, China.

ORCID-Profile: Congjun Jiang

Förderung

  • Longhu Talent Project of Bengbu Medical University
  • Natural Science Innovation Program for Master's Students at Bengbu Medical University

Zitieren

APA

Gao, L., Xie, Q., Zhou, Z., Zhang, W., Sun, H., Yue, Z., & Jiang, C. (2026). Ginsenoside Rg3 Ameliorates Psoriasis‐Like Dermatitis through Inhibition of NF‐κB/NLRP3 Inflammasome Signaling and Regulating Th17/Treg Balance. Immunity, Inflammation and Disease, 14(2). https://doi.org/10.1002/iid3.70362

Vancouver

Gao L, Xie Q, Zhou Z, Zhang W, Sun H, Yue Z, et al. Ginsenoside Rg3 Ameliorates Psoriasis‐Like Dermatitis through Inhibition of NF‐κB/NLRP3 Inflammasome Signaling and Regulating Th17/Treg Balance. Immunity, Inflammation and Disease. 2026;14(2). doi:10.1002/iid3.70362

BibTeX
@article{Gao2026,
  author = {Gao, Liyun and Xie, Qingge and Zhou, Zhaoli and Zhang, Wanlu and Sun, Huiya and Yue, Zhen and Jiang, Congjun},
  title = {Ginsenoside Rg3 Ameliorates Psoriasis‐Like Dermatitis through Inhibition of NF‐κB/NLRP3 Inflammasome Signaling and Regulating Th17/Treg Balance},
  journal = {Immunity, Inflammation and Disease},
  year = {2026},
  volume = {14},
  number = {2},
  doi = {10.1002/iid3.70362}
}
Kostenlos starten →